Abstract:Background: Clinical application of doxorubicin (DOX) is restricted due to its cardiotoxicity, reinforcing the significance of exploring new strategies to counteract DOX-induced cardiotoxicity. The present work aimed to investigate the ameliorative impact of combination therapy with nicotinamide mononucleotide (NMN) and troxerutin (TXR) on DOX-induced cardiotoxicity, with mitochondrial function/biogenesis and inflammatory response approach. Methods: Male Wistar rats (n = 30, 250-300 g) were divided into groups with/without DOX and/or NMN and TXR, alone or in combination. Rats underwent 6 consecutive intraperitoneal injections of DOX (cumulative dose: 12 mg/kg). NMN (100 mg/kg/day; intraperitoneally) and/or TXR (150 mg/kg/day; orally) were administered for 28 days before DOX challenge. Seven days following the last injection of DOX, evaluation of cardiac histopathological changes, BNP and LDH levels, mitochondrial function (membrane potential, ROS generation, and ATP levels), expression of proteins involved in mitochondrial biogenesis (PGC-1α, NRF1, and TFAM), and inflammatory cytokines (TNF-α, IL-1β, and IL-6) was performed. Results: Combination of NMN and TXR significantly decreased the severity of histopathological damages, and BNP and LDH levels (P < 0.01 to P < 0.001). It also restored mitochondrial functional endpoints, and expression of proteins involved in mitochondrial biogenesis (P < 0.05 to P < 0.001), and decreased inflammatory cytokines (P < 0.01 to P < 0.001). The positive impacts of this combination therapy were more potent as compared to monotherapies. Conclusions: These findings shed new light on the understanding of additive properties of NMN/TXR combination therapy in protecting against DOX-induced cardiotoxicity. The cardioprotective effect of this combination therapy may be mediated in part through the restoration of mitochondrial function/biogenesis associated with the PGC-1α/NRF1/TFAM pathway, and suppression of inflammatory response.

Nicotinamide Mononucleotide Supplementation Alleviates Doxorubicin-Induced Multi-Organ Fibrosis

Nicotinamide mononucleotide attenuates doxorubicin-induced cardiotoxicity by reducing oxidative stress, inflammation and apoptosis in rats

NMNATs Expression Inhibition Mediated NAD+ Deficiency Plays a Critical Role in Doxorubicin-Induced Hepatotoxicity in Mice.

Nicotinamide riboside promotes autolysosome clearance in preventing doxorubicin-induced cardiotoxicity.

NAD+ administration decreases doxorubicin-induced liver damage of mice by enhancing antioxidation capacity and decreasing DNA damage

Nicotinamide Mononucleotide Attenuates Isoproterenol-Induced Cardiac Fibrosis by Regulating Oxidative Stress and Smad3 Acetylation.

The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update

Nicotinamide Mononucleotide Attenuates Renal Interstitial Fibrosis after AKI by Suppressing Tubular DNA Damage and Senescence

Short-term Administration of Nicotinamide Mononucleotide Preserves Cardiac Mitochondrial Homeostasis and Prevents Heart Failure.

Nicotinamide Mononucleotide Inhibits Hepatic Stellate Cell Activation to Prevent Liver Fibrosis Via Promoting PGE2 Degradation

Combination of nicotinamide mononucleotide and troxerutin induces full protection against doxorubicin-induced cardiotoxicity by modulating mitochondrial biogenesis and inflammatory response

High-Dosage NMN Promotes Ferroptosis to Suppress Lung Adenocarcinoma Growth through the NAM-Mediated SIRT1-AMPK-ACC Pathway

Nicotinamide Increases the Sensitivity of Chronic Myeloid Leukemia Cells to Doxorubicin Via the Inhibition of SIRT1

Nicotinamide Mononucleotide Alleviates Osteoblast Senescence Induction and Promotes Bone Healing in Osteoporotic Mice

Nicotinic Acid Riboside Regulates Nrf-2/P62-Related Oxidative Stress and Autophagy to Attenuate Doxorubicin-Induced Cardiomyocyte Injury

Nicotinamide mononucleotide attenuates HIF-1a activation and fibrosis in hypoxic adipose tissue <i>via</i> NAD<SUP>+</SUP>/SIRT1 axis

Nicotinamide mononucleotide attenuates HIF-1α activation and fibrosis in hypoxic adipose tissue via NAD+/SIRT1 axis

Nicotinamide Mononucleotide Ameliorates Silica-Induced Lung Injury Through the Nrf2-Regulated Glutathione Metabolism Pathway in Mice.

Nicotinamide mononucleotide as a therapeutic agent to alleviate multi-organ failure in sepsis

Nicotinamide Mononucleotide: Research Process in Cardiovascular Diseases

Nicotinamide Mononucleotide Protects Against High-Fat-diet-induced Atherosclerosis in Mice and Dampens Aortic Inflammation and Oxidative Stress